Biotech Archives - Page 717 of 733

1 minute read

Ultragenyx Shares Tumble On Initial Efficacy Missing Expectations, This Analyst Sees ‘Viable Path Forward”

July 19, 2:51 PM

Earlier today, Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) released updated interim GTX-102 data, including Day 128 assessments from 9 patients. The Overall CGI-C-AS…

RARE

1 minute read

‘As of today, 639 people have tested positive for orthopoxvirus in NYC, which is presumed to be monkeypox.’ – Tweet By nychealthy

By Benzinga Newsdesk

July 19, 2:01 PM

https://twitter.com/nycHealthy/status/1549454091939713025

AEMD

1 minute read

Pfizer And BioNTech Complete Submission To European Medicines Agency For Omicron Ba.1 Adapted Bivalent Vaccine Candidate

By Benzinga Newsdesk

July 19, 1:46 PM

- Reuters

BNTX

1 minute read

HC Wainwright Initiates Coverage On Upcoming Complement Franchise Company Apellis Pharmaceuticals

By Vandana Singh

July 19, 1:09 PM

HC Wainwright has initiated coverage on Apellis Pharmaceuticals Inc (NASDAQ:APLS) with a Buy rating and a $75 price target. The analyst expects Apellis’s…

APLS

1 minute read

European Commission Signs COVID-19 Drug Procurement Deal With Gilead

By Vandana Singh

July 19, 12:30 PM

Gilead Sciences Inc (NASDAQ:GILD) and the European Commission signed a joint procurement agreement for rapid and equitable access to the COVID-19…

GILD

1 minute read

Scynexis Touts Postive Data For Ibrexafungerp For Vaginal Infections

By Vandana Singh

July 19, 11:51 AM

Scynexis Inc (NASDAQ:SCYX) announced the presentation of positive outcomes from the CANDLE 304s nested sub-study of ibrexafungerp in recurrent vulvovaginal candidiasis…

SCYX

1 minute read

Inovio Lays Out Corporate Reorganization To Extend Cash Runway Into 2024

By Vandana Singh

July 19, 11:35 AM

Inovio Pharmaceuticals Inc (NASDAQ:INO) has implemented a corporate reorganization designed to extend its cash runway and focus on key clinical programs.…

INO

1 minute read

Impel Commences Mid-Stage Autism Spectrum Disorder Study

By Ragothaman Srinivasan

July 19, 10:50 AM

Impel Pharmaceuticals (NASDAQ: IMPL) has dosed the first patient in a Phase 2a proof-of-concept study of INP105, nasal olanzapine, a widely used atypical, second-generation antipsychotic.

IMPL

1 minute read

FDA Lifts Clinical Hold On Viking Therapeutics’ Rare Metabolic Disorder Study

By Vandana Singh

July 19, 10:44 AM

The FDA has lifted the clinical hold placed on Viking Therapeutics Inc’s (NASDAQ:VKTX) trial of VK0214 in patients with X-linked adrenoleukodystrophy (X-ALD). …

VKTX